Characteristics of Lumbar Disc Herniation with Exacerbation of Presentation Due to Spinal Manipulative Therapy
Medicine 94:e661, Huang, S.L.,et al, 2015
Cauda Equina Syndrome in the Third Trimester
BMJ 395:e078711, Ugas,M.A. & Ashkan,K., 2023
Endovascular Therapy Versus Anticoagulation for Treatment of Cerebral Venous Sinus Thrombosis
Neurologist 27:69-73, Xu, Z.,et al, 2022
Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke
NEJM 380:1795-1803,1865, Ma, H.,et al, 2019
Association of Spinal Manipulative Therapy with Clinical Benefit and Harm for Acute Low Back Pain
JAMA 317:1451-1460,1418, Paige, N.M.,et al, 2017
Endovascular Therapy for Ischemic Stroke with Perfusion-Imaging Selection
NEJM 372:1009-1018, Campbell, B.C.V.,et al, 2015
Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke
NEJM 372:1019-1030, Goyal, M.,et al, 2015
Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke
NEJM 372:DOI:10.1056/NEJMoa1415061, DOI:10.1056 NEJM e1503217, Saver, J.L.,et al, 2015
Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke
NEJM 372:DOI:10.1056 NEJMoa1503780, DOI:1056NEJM e1503217, Jovin, T.G.,et al, 2015
Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke
NEJM 372:2285-2295,2347, Saver, J.L.,et al, 2015
Thrombectomy within 8 hours after Symptom Onset in Ischemic Stroke
NEJM 372:2296-2306,2347, Jovin, T.G.,et al, 2015
Effect of high-dose Simvastatin on Brain Atrophy and Disability in Secondary Progressive Multiple Sclerosis (MS-STAT): A Randomised, Placebo-Controlled, Phase 2 Trial
Lancet 383:2213-2221, Chataway, J.,et al, 2014
Effect of Rituximab in Patients with Leucine-Rich, Glioma-Inactivated 1 Antibody-Associated Encephalopathy
JAMA Neurol 71:896-900, Irani, S.R.,et al, 2014
MR Myelography for Identification of Spinal CSF Leak in Spontaneous Intracranial Hypotension
AJNR 35:2007-2012, Chazen, J.L.,et al, 2014
Efficacy and Safety of Everolimus for Subependymal Giant Cell Astrocytomas Associated with Tuberous Sclerosis Complex (EXIST-1): A Multicenter, Randomized, Placebo-Controlled Phase 3 Trial
Lancet 381:125-132, Franz, D.,et al, 2013
Everolimus Long-Term Safety and Efficacy in Subependymal Giant Cell Astrocytoma
Neurol 80:574-580, Krueger, D.,et al, 2013
The Safety of Thoracentesis in Patients with Uncorrected Bleeding Risk
Ann Am Thoracic Soc 10:336-341, Puchalski, J.T.,et al, 2013
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
NEJM 367:1098-1106,1149, Gold, R.,et al, 2012
Alemtuzumab for Multiples Sclerosis: Who and When to treat?
Lancet 380:1795-1797, 1792, Springer, T. & Kappos, L., 2012
Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011
Decompressive Craniectomy in Diffuse Traumatic Brain Injury
NJM 364:1493-1502, Cooper, D.J.,et al, 2011
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
NEJM 365:1293-1303, OConnor, P.,et al, 2011
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
NEJM 362:416-426, 456, Giovannoni,G.,et al, 2010
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
NEJM 362:387-401, 456, Kappos, L.,et al, 2010
Immunologic, Clinical, and Radiologic Status 14 Months After Cessation of Natalizumab Therapy
Neurol 72:396-401,392, Stuve,O.,et al, 2009
Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis
Arch Neurol 65:1044-1051, Krishnan,C.,et al., 2008
The Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin for the Prevention of Venous Thromboembolism After Acute Ischaemic Stroke (PREVAIL Study): An Open-Label Randomised Comparison
Lancet 369:1347-1355, Sherman,D.G.,et al, 2007
Randomised Controlled Trial of a Short Course of Traditional Acupuncture Compared with Usual Care for Persistent Non-Specific Low Back Pain
BMJ 333:623-626,611, Thomas,K.J.,et al, 2006